Received Apr 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
my daughter used the covid treatment they have and was sick ill for over 2yrs; This is a solicited report received from a Consumer or other non HCP, Program ID. A female patient received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ILLNESS (medically significant), outcome "unknown", described as "my daughter used the covid treatment they have and was sick ill for over 2yrs". Clinical course: The reporter's daughter used the covid treatment (vaccine) and was sick ill for over 2yrs. The reporter's wife and the reporter used Moderna and had no problems. The reporter's assessment of the causal relationship of "my daughter used the covid treatment they have and was sick ill for over 2yrs" with the suspect product(s) BNT162b2 was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.; Sender's Comments: A causal association between the event illness and BNT162b2 cannot be excluded; however, assessment is limited by very limited relevant information, including the absence of a specific diagnosis, vaccination and onset dates, medical history, and concomitant medications. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.